Plain-English translation of NCT06209606 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach to treating multiple myeloma that has come back or stopped responding to standard treatments. The study combines ruxolitinib with a steroid medication () and may add based on how your cancer responds. Researchers will use a new blood test that measures a protein called BCMA to track whether the treatment is working, potentially allowing them to adjust your care faster than traditional methods.
Multiple myeloma can be difficult to treat once it stops responding to standard drugs, and doctors need better ways to quickly tell if a treatment is working so they can make changes sooner. This trial is testing whether this medication combination, guided by a new blood test, can help patients live longer and give doctors an earlier warning when treatment adjustments are needed.
You likely qualify if…
You likely don't qualify if…
You will take the study medications by mouth, with doses that may be adjusted during the first part of the trial. You will have regular clinic visits for blood tests, including the new BCMA blood test to monitor how well the treatment is working. If your cancer shows signs of progressing based on either the BCMA test or standard cancer markers, an additional medication () will be added to your treatment plan.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States